Your browser doesn't support javascript.
loading
[Temporary circulatory assistance by Impella™ in interventional cardiology: Observational study and medico-economic assessment after four years of use]. / Assistance circulatoire temporaire par Impella™ en cardiologie interventionnelle : étude observationnelle et bilan médicoéconomique après quatre ans d'utilisation.
Bouillot, Elodie; Cherpin, Amélie; Remacle Bonnet, Anne; Bonello, Laurent; Peyron, Florence.
Afiliação
  • Bouillot E; Pharmacie à usage intérieur, AP-HM Nord, chemin des Bourrely, 13915 Marseille cedex 20, France. Electronic address: elodie.bouillot@hotmail.fr.
  • Cherpin A; Pharmacie à usage intérieur, AP-HM Nord, chemin des Bourrely, 13915 Marseille cedex 20, France.
  • Remacle Bonnet A; Service d'information médicale, AP-HM Nord, chemin des Bourrely, 13915 Marseille cedex 20, France.
  • Bonello L; Service de cardiologie, AP-HM Nord, chemin des Bourrely, 13915 Marseille cedex 20, France.
  • Peyron F; Pharmacie à usage intérieur, AP-HM Nord, chemin des Bourrely, 13915 Marseille cedex 20, France.
Ann Pharm Fr ; 82(1): 110-120, 2024 Jan.
Article em Fr | MEDLINE | ID: mdl-37923010
ABSTRACT

OBJECTIVES:

During life-threatening emergencies or risky cardiologic interventions, pharmacology can be limited and the use of appropriate medical devices is then necessary. The Impella™ catheter, CP and 2.5, has been referenced for the exclusive use of the interventional cardiology technical platform at Hôpital Nord (AP-HM) in the absence of rapid access to the Extracorporeal Circulation unit. It is a temporary mechanical circulatory support device mainly indicated in refractory cardiogenic shock and coronary angioplasty at high risk of hemodynamic instability. The objective of this study, observational and retrospective, is to carry out a clinical and economic assessment linked to the use of this device over a period of four years (2017-2020).

METHODS:

The criteria relating to the 71 patients (51 Impella™ CP and 20 Impella™ 2.5) and their clinical evolution as well as the costs and valuation of the stays were determined.

RESULTS:

In particular, the Impella™ CP enabled myocardial recovery in 18 out of 51 patients and it was an intermediary in the context of heavier care for 11 patients. The balance between expenditure and valuation shows a deficit of -819,937 euros over the study period, with however a probable margin for improvement.

CONCLUSIONS:

The Impella™ is of clinical interest under very specific conditions. Its high cost and the absence of inclusion on the list of reimbursements in addition to Homogeneous Groups of Stays represent a significant financial burden for health care establishments. Thus, optimizing the rating of future stays is a necessity.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Choque Cardiogênico / Cardiologia Limite: Humans Idioma: Fr Revista: Ann Pharm Fr Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Choque Cardiogênico / Cardiologia Limite: Humans Idioma: Fr Revista: Ann Pharm Fr Ano de publicação: 2024 Tipo de documento: Article